| dc.description.abstract | Background: Lung cancer has a poor prognosis compared to other types of cancer because of the low survival rate. Prognostic factors are measured related to lung cancer and are divided into three: Progression-Free Survival (PFS), Overall Survival (OS), and Survival rate or survival rate. Adenocarcinoma lung cancer is the most common type of NSCLC in the world. There are many significant developments in systemic therapy in treating pulmonary adenocarcinoma, including chemotherapy approaches and targeted therapy with EGFR-TKI, but the patient is still not fully treatable. The exact data regarding the prognostic factors of patients with lung adenocarcinoma are still not known between EGFR TKI treatment and chemotherapy at H. Adam Malik Hospital Medan.
Objective: This study aims to determine the prognostic factors in lung cancer patients with lung adenocarcinoma who received chemotherapy and EGFR TKI at H. Adam Malik Hospital, Medan.
Methods: This study is an analytic study with a retrospective cohort design conducted at the Oncology Polyclinic at H Adam Malik Hospital Medan from January 2017 to December 2019. The subjects of this study were all lung adenocarcinoma patients who received chemotherapy and EGFR treatment for TKI. . Overall demographic data and clinical evaluation data of patients who have been carried out will be subjected to statistical tests to assess prognostic factors of Adenocarcinoma patients who have been treated at H. Adam Malik Hospital, Medan.
Results: In the EFGR group of TKI; totaling 59 people (61.5%) male gender; 56 people (58.3%) aged < 60 years; 51 people (53.1%) of the Batak tribe; 51 people (53.1%) are active smokers' 25 people (26%) severe Brinkman Index; 22 people (22.9%) with a history of TB; 17 people (17.7%) Family history of malignancy; 7 people (41.2%) had a family history of breast cancer; 80 people (83.3%) showed the type of adenocarcinoma; stage IV A numbered 59 people (61.5%), followed by stage IV B amounted to 14 people (14.6%); PS 1 numbered 69 people (71.9%); 50 people (52.1%) had pleural metastases. Based on EGFR mutations, the most mutations were exon 19 in/del mutations, totalling 37 people (38.5%), followed by exon 21 L858R mutations totalling 30 people (31.2%). While in the chemotherapy group; totaling 36 people (66.7%) male gender; 33 people (61.1%) aged < 60 years; 33 people (61.1%) of the Batak tribe; 34 people (63%) are active smokers; and 21 people (38.9%) severe Brinkman Index; 20 people (37%) with a history of TB; 18 people (33.3%) Family history of malignancy; 7 people (38.9%) had a family history of breast cancer; 54 people (100%) showed the type of adenocarcinoma; stage IV A numbered 35 people (64.8%) followed by stage IV B amounted to 15 people (27.8%); PS 1 consisted of 30 people (55.6%); 30 people (55.6%) had pleural metastases. The median PFS of chemotherapy patients was six months (95% CI: 4,841 – 7,159 months). The median PFS in lung adenocarcinoma patients receiving EGFR TKI therapy was six months (95% CI: 4,720 – 7,280 months). A log-rank test showed a significant difference in median PFS between adenocarcinoma patients receiving EGFR TKI and chemotherapy (p= 0.013).
Conclusion: There was a significant difference in the median PFS between patients with lung adenocarcinoma who received EGFR TKI and chemotherapy | en_US |
